Recce (ASX:RCE) share price edges higher after patent approval

The pharmaceutical company is making progress of late. Here are the details
The post Recce (ASX:RCE) share price edges higher after patent approval appeared first on The Motley Fool Australia. –

The Recce Pharmaceuticals Ltd (ASX: RCE) share price ended the day higher after the company secured a patent in the United States.

At the closing bell, the pharmaceutical company’s shares finished the day up 3.27% to $1.10.

Let’s take a closer look at what Recce announced to the ASX this morning.

Recce furthers patent protection

According to its release, the United States Patent and Trademark Office has granted Patent Family 3 to Recce anti-infectives.

Titled “Anti-Virus Agent and Method for Treatment of Viral Infections”, the patent furthers the company’s marketing and manufacturing property until February 2037.

The approved claims relate to its flagship drug, Recce 327, and anti-viral formulation, Recce 529. They are as follows:

Composition/method of manufacture of Recce anti-infectives;
Use of Recce 327 or Recce 529 for the treatment of viruses having a lipid envelope or coat, examples being SARS-CoV-2 and Corona viruses, Influenza viruses, HIV, Hepatitis, Ross River and Herpes viruses; and
Administration of Recce 327 or Recce 529 by oral, injection, inhalation and transdermal dose applications.

Recce’s lead drug candidate (Recce 327) is being developed to treat blood infections and sepsis.

Investors appeared buoyed by this latest development, sending the Recce share price higher on Thursday.

According to World Atlas, the US is the largest pharmaceutical market in the world, valued at $33.97 billion. The country’s stringent processes in developing and manufacturing drugs has led to some of the best-selling products across the globe.

Just this week, China also granted Recce Patent Family 3 to its anti-infectives. This leaves Australia as the only remaining nation yet to approve the patent. China, Japan, Europe and now the United States have all authorised Recce’s Family 3 patent.

Recce CEO James Graham said:

Recce’s intellectual property portfolio continues to grow in-line with our business strategy and the unprecedented global infectious disease crisis before us. We are thrilled to see that our anti-viral patent granted in the USA, the largest pharmaceutical market in the world; with yet further market-monopolies reinforcing the unique opportunities among a significant range of both bacterial and viral pathogens.

Recce share price summary

Despite today’s rise, Recce shares have had a disappointing 12 months, falling more than 15%. However, year-to-date, the company’s share price is slightly up by 5%.

Recce has a market capitalisation of roughly $192 million, ranking as the 722nd largest company on the ASX.

The post Recce (ASX:RCE) share price edges higher after patent approval appeared first on The Motley Fool Australia.

Should you invest $1,000 in Recce right now?

Before you consider Recce, you’ll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Recce wasn’t one of them.

The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of May 24th 2021

More reading

Why the Recce (ASX:RCE) share price is racing 5% higher today

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

Trade The World Anywhere & Anytime!

Mobile app platform with over 50,000 global listed securities across 12 markets (over 70% global market capitalisation), right from your Android or iOS device.

Integrated with exclusive trading idea and investment analysis tools to help you find actionable insight on virtually every financial instrument across our 12 global markets, to help you optimise your trading strategies.

Refer Your Friends

Tell your friends about Monex and gift them FREE access to our trading tools.

We respect your privacy and will only send this one email notification to your friends. 

Share With Your Friends

Share on facebook
Share on twitter
Share on linkedin

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;

To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.

An active and funded account with a positive trading balance is required to continue to have access to the tools;

Although the tools are available to you indefinitely, Monex Securities may at it’s discretion disable access to the tools in the future;

Monex securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

Important Notice
iOS & Android App - 12 International Markets & Over 70% Global Market Cap. $0 Brokerage On US Trades. Click Here!